Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells
and have predictive value supporting personalized medicine. Here we describe a large …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

The field of non-coding RNA (ncRNA) has made significant progress in understanding the
pathogenesis of diseases and has broadened our knowledge towards their targeting …

In colorectal cancers, the tumor microenvironment plays a key role in prognosis and therapy
efficacy. Patient-derived tumor organoids (PDTO) show enormous potential for preclinical …

Background The consensus molecular subtypes (CMSs) of colorectal cancer (CRC) capture
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …

Background Colorectal cancer (CRC) is the second most common solid organ cancer.
Traditional treatment is with surgery and chemotherapy. Immunotherapy has recently …

Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …